Vasopressin in chronic kidney disease: An elephant in the room

Kidney International

Volumn 76, Issue 9, 2009, Pages 925-928

  Torres, Vicente E ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DEOXYCORTICOSTERONE ACETATE; DESMOPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MOZAVAPTAN; RWJ 676070; SATAVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; YM 218;

BLOOD SMEAR; CHRONIC KIDNEY DISEASE; DISEASE COURSE; EPITHELIUM CELL; GLOMERULOSCLEROSIS; KIDNEY BLOOD FLOW; MESANGIUM CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEINURIA; STREPTOZOCIN DIABETES;

EID: 70350070609     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.325     Document Type: Note

References (38)

1. Perico N, Zoja C, Corna D et al. V 1/V2Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009; 76: 960-967.
2. Brenner BM. AMGEN International Prize: the history and future of renoprotection. Kidney Int 2003; 64: 1163-1168.
3. Bardoux P, Bruneval P, Heudes D et al. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755-1763.
4. Bardoux P, Martin H, Ahloulay M et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci USA 1999; 96: 10397-10402.
5. Bhandari SS, Loke I, Davies JE et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009; 116: 257-263.
6. Bouby N, Bachmann S, Bichet D et al. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258: F973-F979.
7. Sugiura T, Yamauchi A, Kitamura H et al. H ighwate r intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int 1999; 55: 1800-1810.
8. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 1999; 65: 991-1004.
9. Brooks DP, Solleveld HA, Contino LC. Vasopressin and the pathogenesis of chronic renal failure. Br J Pharmacol 1990; 100: 79-82.
10. Hebert LA, Greene T, Levey A et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41: 962-971.
11. Kwon TH, Frokiaer J, Knepper MA et al. Reduced AQP1,-2, and-3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol 1998; 275: F724-F741.
12. Carmosino M, Brooks HL, Cai Q et al. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. Am J Physiol Renal Physiol 2007; 292: F351-F360.
13. Mutig K, Paliege A, Kahl T et al. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol 2007; 293: F1166-F1177.
14. Terada Y, Tomita K, Nonoguchi H et al. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest 1993; 92: 2339-2345.
15. Gunnet JW, Wines P, Xiang M et al. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist. Eur J Pharmacol 2008; 590: 333-342.
16. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001; 51: 372-390.
17. Bouby N, Ahloulay M, Nsegbe E et al. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7: 842-851.
18. Trinh-Trang-Tan MM, Bouby N, Doute M et al. Effect of long-and short-term antidiuretic hormone availability on internephron heterogeneity in the adult rat. Am J Physiol 1984; 246: F879-F888.
19. Anastasio P, Cirillo M, Spitali L et al. Level of hydration and renal function in healthy humans. Kidney Int 2001; 60: 748-756.
20. Andersen LJ, Andersen JL, Schutten HJ et al. Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans. Am J Physiol 1990; 259: R53-R60.
21. Bankir L, Bouby N,Trinh-Trang-Tan MM et al. D i r e c t and indirect cost of urea excretion. Kidney Int 1996; 49: 1598-1607.
22. Bankir L, Perucca J, Weinberger MH. Ethnic differences in urine concentration: possible relationship to blood pressure. Clin J Am Soc Nephrol 2007; 2: 304-312.
23. Perucca J, Bouby N, Valeix P et al. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 2007; 292: R700-R705.
24. Loichot C, Krieger JP, De Jong W et al. Shear stress modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 555-561.
25. Cowley AW Jr. Control of the renal medullary circulation by vasopressin V1 and V2 receptors in the rat. Exp Physiol 2000; 85 (Spec No): 223S-231S.
26. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989; 256: F274-F278.
27. Fisher RD, Grunfeld JP, Barger AC. Intrarenal distribution of blood flow in diabetes insipidus: role of ADH. Am J Physiol 1970; 219: 1348-1358.
28. Davis JM, Schnermann J. The effect of antidiuretic hormone on the distribution of nephron filtration rates in rats with hereditary diabetes insipidus. Pflugers Arch 1971; 330: 323-334.
29. Yamada K, Nakano H, Nishimura M et al. Effect of AVP.V 1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP.V 1-receptor. J Diabetes Complications 1995; 9: 326-329.
30. Bardoux P, Bichet DG, Martin H et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506.
31. Aoyagi T, Izumi Y, Hiroyama M et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol 2008; 295: F100-F107.
32. Perucca J, Bichet DG, Bardoux P et al. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 2008; 19: 1721-1731.
33. O'Connor PM, Cowley AW Jr. Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway. Am J Physiol Renal Physiol 2007; 293: F526-F532.
34. Tahara A, Tsukada J, Tomura Y et al. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy. Vascul Pharmacol 2007; 46: 463-469.
35. Tahara A, Tsuk ada J, Tomura Y et al. Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. Pharmacol Res 2008; 57: 142-150.
36. Torres VE. Role of vasopressin antagonists. Clin J Am Soc Nephrol 2008; 3: 1212-1218.
37. Alonso G, Galibert E, Boulay V et al. Sustained elevated levels of circulating vasopressin selectively stimulate the proliferation of kidney tubular cells via the activation of V2 receptors. Endocrinology 2009; 150: 239-250.
38. Yang B, Bankir L. Urea and urine concentrating ability: new insights from studies in mice. Am J Physiol Renal Physiol 2005; 288: F881-F896.